DMTX Dimension Therapeutics, Inc.

1.05
-0.10  -9%
Previous Close 1.15
Open 1.10
Price To book 0.61
Market Cap 26.30M
Shares 25,043,000
Volume 129,300
Short Ratio 1.89
Av. Daily Volume 109,469

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiated December 2016. Initial data due 2H 2017.
DTX301
Ornithine Transcarbamylase (OTC) Deficiency
Phase 1/2 initial data released January 31, 2017. Announced May 10, 2017 that program will be discontinued.
DTX101
hemophilia B

Latest News

  1. Dimension Therapeutics reports 1Q loss
  2. Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
  3. Dimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy (ASGCT) Annual Meeting
  4. ETFs with exposure to Dimension Therapeutics, Inc. : April 7, 2017
  5. Edited Transcript of DMTX earnings conference call or presentation 9-Mar-17 1:30pm GMT
  6. Dimension Therapeutics, Inc. :DMTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  7. Dimension Therapeutics, Inc. :DMTX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  8. Can The Uptrend Continue for Dimension Therapeutics (DMTX)?
  9. Dimension Therapeutics Announces Full Year 2016 Financial Results and Recent Updates Across Rare and Metabolic Disease Portfolio and in HeLa Manufacturing
  10. Dimension Therapeutics to Hold Full Year 2016 Financial Results and Recent Program Updates Conference Call
  11. Lifshitz & Miller LLP Announces Investigation of BT Group plc, Celadon Group, Inc., Community Health Systems, Inc., Dimension Therapeutics, Inc., Home Capital Group Inc., Lifevantage Corporation, OvaScience, Inc. and Under Armour, Inc.
  12. Newman Ferrara LLP Announces Corporate Governance Investigation of Dimension Therapeutics Inc.
  13. Cerner's EHR Platform to Enhance Health Care at San Juan NGO
  14. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Dimension Therapeutics, Inc.
  15. vTv Therapeutics (VTVT) in Focus: Stock Moves 6.7% Higher
  16. Is Dimension Therapeutics Inc (DMTX) Going to Burn These Hedge Funds?